New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
about
Insulin Protects Hepatic Lipotoxicity by Regulating ER Stress through the PI3K/Akt/p53 Involved Pathway Independently of Autophagy InhibitionPharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin.Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.A Large Difference in Dose Timing of Basal Insulin Introduces Risk of Hypoglycemia and Overweight: A Cross-Sectional StudySGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management?Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.Novel Concentrated Insulin Delivery Devices: Developments for Safe and Simple Dose Conversions.Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials.Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature.[Modern antihyperglycaemic agents--what is the patient benefit?].
P2860
Q28834030-6C4D6DEA-1601-4643-88AF-236E13BAA6BCQ30248803-2F2832EC-66CC-4F6B-BDBD-C3D72B168EE7Q37054680-386B8B6A-980D-4E3D-8F0F-D03854F0B796Q37538487-9D0BCA21-40AF-473D-B155-6E9E3FFAA7E6Q37737467-71479325-ACBF-4360-B65D-4393CFAEBFA8Q38768667-FFA6AA6F-6E30-4234-8C57-6DDE74A4E0C6Q39791634-3CFF7381-A761-4B89-845F-0BEE1D874CCCQ44372707-BC2EB2A3-BDAB-443B-8838-1AA0C8A7B3B1Q46199321-3EA747CD-F760-48B7-BCC2-4597ECFAAC81Q52591845-F8E1A5F7-89C8-400D-A8FC-F934CFCD869CQ52605864-F4B2D75A-4149-47E2-B7DB-D45F180449D3Q53790237-3D5F892D-7516-470B-A2B2-ADA67A79CFB4
P2860
New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
@en
type
label
New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
@en
prefLabel
New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
@en
P2860
P356
P1476
New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
@en
P2093
John R White
P2860
P304
P356
10.1177/1060028015597915
P407
P577
2015-08-03T00:00:00Z